EUROFINS CEREP-REGR (ALECR.PA) Stock Fundamental Analysis
Europe - EPA:ALECR - FR0013256518 - Common Stock
16100 EUR
-1600 (-9.04%)
Overall ALECR gets a fundamental rating of 4 out of 10. We evaluated ALECR against 19 industry peers in the Life Sciences Tools & Services industry. Both the profitability and the financial health of ALECR get a neutral evaluation. Nothing too spectacular is happening here. ALECR has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
ALECR had positive earnings in the past year.
Each year in the past 5 years ALECR has been profitable.
In the past 5 years ALECR always reported negative operating cash flow.
1.2 Ratios
ALECR's Return On Assets of 9.29% is amongst the best of the industry. ALECR outperforms 88.89% of its industry peers.
With a decent Return On Equity value of 10.82%, ALECR is doing good in the industry, outperforming 72.22% of the companies in the same industry.
ALECR has a worse Return On Invested Capital (5.81%) than 61.11% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ALECR is in line with the industry average of 8.08%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| ROIC | 5.81% |
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
1.3 Margins
ALECR has a Profit Margin of 16.86%. This is amongst the best in the industry. ALECR outperforms 88.89% of its industry peers.
In the last couple of years the Profit Margin of ALECR has grown nicely.
ALECR has a Operating Margin of 12.72%. This is in the lower half of the industry: ALECR underperforms 72.22% of its industry peers.
In the last couple of years the Operating Margin of ALECR has declined.
With an excellent Gross Margin value of 85.67%, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Gross Margin of ALECR has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.72% | ||
| PM (TTM) | 16.86% | ||
| GM | 85.67% |
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
2. Health
2.1 Basic Checks
ALECR has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, ALECR has more shares outstanding
The debt/assets ratio for ALECR is higher compared to a year ago.
2.2 Solvency
ALECR has an Altman-Z score of 11.46. This indicates that ALECR is financially healthy and has little risk of bankruptcy at the moment.
ALECR's Altman-Z score of 11.46 is amongst the best of the industry. ALECR outperforms 100.00% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that ALECR is not too dependend on debt financing.
ALECR has a better Debt to Equity ratio (0.00) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.46 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ALECR has a Current Ratio of 7.27. This indicates that ALECR is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.27, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
A Quick Ratio of 6.83 indicates that ALECR has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 6.83, ALECR belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.27 | ||
| Quick Ratio | 6.83 |
3. Growth
3.1 Past
ALECR shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.41%.
Measured over the past years, ALECR shows a decrease in Earnings Per Share. The EPS has been decreasing by -3.78% on average per year.
The Revenue has decreased by -7.94% in the past year.
The Revenue has been growing slightly by 5.22% on average over the past years.
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
ALECR is valuated rather expensively with a Price/Earnings ratio of 22.52.
61.11% of the companies in the same industry are more expensive than ALECR, based on the Price/Earnings ratio.
The average S&P500 Price/Earnings ratio is at 25.89. ALECR is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.52 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
ALECR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EPA:ALECR (10/28/2025, 7:00:00 PM)
16100
-1600 (-9.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap161.00M
Revenue(TTM)41.00M
Net Income(TTM)7.25M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.52 | ||
| Fwd PE | N/A | ||
| P/S | 3.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.4 | ||
| P/tB | 2.49 | ||
| EV/EBITDA | N/A |
EPS(TTM)715
EY4.44%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS4300
BVpS6700
TBVpS6476
PEG (NY)N/A
PEG (5Y)N/A
Graham Number10382
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.29% | ||
| ROE | 10.82% | ||
| ROCE | 7.94% | ||
| ROIC | 5.81% | ||
| ROICexc | 5.81% | ||
| ROICexgc | 6% | ||
| OM | 12.72% | ||
| PM (TTM) | 16.86% | ||
| GM | 85.67% | ||
| FCFM | N/A |
ROA(3y)11.69%
ROA(5y)12.73%
ROE(3y)14.25%
ROE(5y)16.06%
ROIC(3y)8.88%
ROIC(5y)10.64%
ROICexc(3y)10.25%
ROICexc(5y)11.89%
ROICexgc(3y)10.71%
ROICexgc(5y)12.51%
ROCE(3y)12.09%
ROCE(5y)14.49%
ROICexgc growth 3Y-34.97%
ROICexgc growth 5Y-16.9%
ROICexc growth 3Y-34.63%
ROICexc growth 5Y-16.09%
OM growth 3Y-22.69%
OM growth 5Y-3.77%
PM growth 3Y-8.91%
PM growth 5Y4.87%
GM growth 3Y-0.31%
GM growth 5Y12.87%
F-ScoreN/A
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.27 | ||
| Quick Ratio | 6.83 | ||
| Altman-Z | 11.46 |
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.41%
EPS 3Y-28.46%
EPS 5Y-3.78%
EPS Q2Q%-2.25%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.94%
Revenue growth 3Y-1.31%
Revenue growth 5Y5.22%
Sales Q2Q%-8.7%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-33.62%
EBIT growth 3Y-23.7%
EBIT growth 5Y1.26%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A
EUROFINS CEREP-REGR / ALECR.PA FAQ
What is the ChartMill fundamental rating of EUROFINS CEREP-REGR (ALECR.PA) stock?
ChartMill assigns a fundamental rating of 4 / 10 to ALECR.PA.
What is the valuation status for ALECR stock?
ChartMill assigns a valuation rating of 1 / 10 to EUROFINS CEREP-REGR (ALECR.PA). This can be considered as Overvalued.
How profitable is EUROFINS CEREP-REGR (ALECR.PA) stock?
EUROFINS CEREP-REGR (ALECR.PA) has a profitability rating of 5 / 10.
What is the valuation of EUROFINS CEREP-REGR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for EUROFINS CEREP-REGR (ALECR.PA) is 22.52 and the Price/Book (PB) ratio is 2.4.